GSK Reports Strong ADC Data in Ovarian Cancer Study
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
